###### Strengths and limitations of this study

-   We performed a comprehensive systematic search for eligible studies. This is the first systematic review and meta-analysis to specifically evaluate the association between statin use and the risk of herpes zoster.

-   The studies included in our meta-analysis included many participants with long-term follow-up time. Literature eligibility was assessed by two investigators independently. No significant publication bias was found.

-   This was a meta-analysis of observational studies, allowing the conclusion that an association exists, but this type of analysis cannot determine if a causal relationship exists.

-   We found significant heterogeneity across studies, due to regional differences. The study by Chung *et al* contributed much heterogeneity, but the result remained significant after exclusion of this study.

-   We did not study the effects of different statins on the risk of herpes zoster due to insufficient data. Some results might be influenced by the conversion of other measures to OR.

Introduction {#s1}
============

Statins (3-hydroxy-3-methylglutaryl-coenzyme A reductase inhibitors) are used to lower levels of low-density lipoprotein cholesterol, and are widely prescribed for the prevention of cardiovascular diseases (CVD).[@R1] In addition to acting as potent lipid-lowering agents, statins have immunomodulating properties that may increase the risk of infectious diseases.[@R3]

Herpes zoster occurs as a reactivation of a latent infection with varicella zoster virus (VZV), causing postherpetic neuralgia and acute and chronic pain.[@R5] The pain caused by inflammation and neuronal destruction can be disruptive to daily activities, decreasing quality of life for the elderly.[@R6] As statins are commonly prescribed worldwide, if statin use increases the risk of VZV reactivation, this adverse effect may present substantial public health implications.

Many epidemiological studies have reported an association between statin use and the risk of herpes zoster,[@R7] but there has been no meta-analysis to systematically evaluate all available data. To address this need, we conducted a comprehensive systematic review and meta-analysis of observational studies to assess the association between statin use and the risk of herpes zoster.

Methods {#s2}
=======

Search strategy {#s2a}
---------------

We followed the guidelines described in the Meta-Analysis of Observational Studies in Epidemiology.[@R13] We first systematically searched PubMed and Embase databases on 20 December 2015 for studies of the association between statins and herpes zoster. To ensure our study included all available up-to-date results, we systematically did an additional database search of PubMed, Embase, Web of Science and Cochrane on 20 July 2018. We also checked the references of included studies and reviews. The search focused on statins and herpes zoster as subject terms and keywords. The detailed search strategies are shown in the online [supplementary material 1](#SP1){ref-type="supplementary-material"}.
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Study selection {#s2b}
---------------

Two investigators independently assessed literature eligibility, and disagreements were settled by discussion and consensus. Articles were included in the systematic review if: (1) the authors reported data from an original, peer-reviewed study (ie, not review articles or conference abstracts); (2) the study was a cohort study or case-control study (case reports were not included due to a lower quality of evidence-based medical evidence); and (3) the authors reported risk estimates of herpes zoster among users of statins. For studies that resulted in multiple publications, we included the article with the longest follow-up time or that presented the most incident cases. We identified articles that qualified for further examination by performing an initial screen of identified titles and abstracts, followed by a full-text review.

Data extraction {#s2c}
---------------

Two investigators independently extracted the following information from the studies: authors, publication year, study region, study design, risk estimates (95% CI), patient mean age, follow-up time or study period, female percentage, diagnosis of herpes zoster, assessment of the use of statins, types of statins used, number of study participants (number of case participants and control participants for case-control studies, and the number of exposures and non-exposures for cohort studies) and confounder adjustment. If any information was unavailable or not clear from a published report, we collected the relevant data by directly corresponding with the authors.

We used the Newcastle-Ottawa Quality Assessment Scale[@R14] to evaluate the quality of each study with consideration of selection, comparability and exposure for non-randomised studies.[@R15] For the case-control and cohort studies, different evaluation criteria were used. A total score of less than or equal to 3 was considered poor quality, a score of 4--6 was considered moderate quality and a score of 7--9 was deemed high quality. Poor quality studies were excluded in the sensitivity analysis. The details of study assessment are presented in online [supplementary material 2](#SP2){ref-type="supplementary-material"}.
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Data synthesis and analysis {#s2d}
---------------------------

The fully adjusted risk estimates were used to estimate the association between statin use and the risk of herpes zoster. The HR and relative ratio values were regarded equivalent to the OR for the low incidence of diseases. Forest plots were made to visually assess the ORs and the corresponding 95% CI across studies. The heterogeneity across studies was assessed by the Cochrane Q statistic (using a significance level of p\<0.10) and the I^2^ statistic (this parameter ranges from 0% to 100% with lower values corresponding to less heterogeneity).[@R16] The ORs were pooled using the DerSimonian and Laird inverse-variance-weighted random-effect models.[@R17]

The influences of participant characteristics on the results were assessed by subgroup analyses of study type, study region, number of study participants, female percentage, mean age and the quality of the study. We omitted each study individually to test the influence of studies on the heterogeneity and the robustness of the analysis.[@R18] The potential publication bias was examined by visual inspection of the funnel plot and the Egger's test result (p\<0.10).[@R19]

The analyses were performed with STATA V.14.1 (Stata Corp). A p value\<0.05 was considered statistically significant, except where otherwise specified.[@R20]

Patient and public involvement {#s2e}
------------------------------

No patients and/or the general public were involved in this study.

Results {#s3}
=======

Literature search {#s3a}
-----------------

Two investigators independently assessed study eligibility and performed data extraction. The results were compared, discussed, and consensus was reached. The initial search yielded 249 articles. Among these, 38 duplicate articles were identified. An additional study was identified by a search of Google Scholar using search terms stains and herpes zoster. After the first round of screening based on titles and abstracts, 15 articles were retained and subjected to further review. After detailed examination, nine articles were excluded.[@R21] Seven studies were excluded because they were reviews, one study was excluded because it was a conference abstract and one study was excluded because it was a letter. Ultimately, we included six articles[@R7] in the meta-analysis ([figure 1](#F1){ref-type="fig"}).

![Flow chart of the meta-analysis of association between statin use and herpes zoster.](bmjopen-2018-022897f01){#F1}

Study characteristics {#s3b}
---------------------

The characteristics of the included six studies are presented in [table 1](#T1){ref-type="table"}. The six studies were published between 2008 and 2018. Two studies were evaluated as high quality,[@R11] and the rest were of moderate quality; no study was excluded for poor quality. Three studies were performed in Asia,[@R8] two in North America[@R7] and one in Europe.[@R12] The participants of one study were limited to veterans.[@R10] Follow-up duration ranged from 1.95 to 11 years, with a median of 5.9 years. The mean age of study participants was between 51.7--73 years, and the participants included in one study were all older than 66.[@R7] The largest study[@R12] included 694 295 participants, and the smallest study[@R10] included 18 951 participants. All studies had roughly a 50% sex ratio except one study with only 3.3 per cent women.[@R10] Three studies[@R7] included seven types of statins, two studies[@R8] included six types of statins and one study[@R10] included five types of statins. In the included studies, the diagnosis of herpes zoster all relied on the International Classification of Diseases code. The assessment of stain use relied on prescriptions or medication records. The adjustment for potential confounding factors differed between studies, and most risk estimates were adjusted for age and gender.

###### 

Characteristics of studies included in the meta-analysis of the relationship between statin use and herpes zoster

  -----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Study                Study\   Study\                 Mean\     Follow-up or period\   Female\   Diagnosis of herpes zoster                                                                                         Assessment of statin use   Types of statins                                                                              Case/control or exposure/non-exposure   OR (95% CI)      Confounder adjustment                                                                                                                                                                                                                         Quality assessment\
                       region   design                 age\      (years)                (%)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          (NOS)
                                                       (years)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       
  -------------------- -------- ---------------------- --------- ---------------------- --------- ------------------------------------------------------------------------------------------------------------------ -------------------------- --------------------------------------------------------------------------------------------- --------------------------------------- ---------------- --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- --------------------------------
  Kim *et al*,\        Korea    Retrospective cohort   52.6      11                     51        ICD code                                                                                                           Prescription               Atorvastatin, rosuvastatin, pitavastatin, simvastatin, ﬂuvastatin, pravastatin, lovastatin    25 726/25 726                           1.25\            Propensity score matching: age, gender, economic class, HPN, diabetes, dyslipidaemia, IHD, TIA, HF, AF, VHD, carotid stenosis, PVD, CRD, CLD, CPD, RA, IBD, malignancy, transplantation recipients of solid organs or HSCT, HIV, depression   Selection: 3\
  2018[@R11]                                                                                                                                                                                                                                                                                                                                                                          (1.15 to 1.37)                                                                                                                                                                                                                                                 Comparability: 2\
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     Outcome: 2

  Matthews *et al*,\   UK       Case control           59.5      2000--2011             60.7      ICD code                                                                                                           Prescription               Atorvastatin, rosuvastatin, cerivastatin, simvastatin, fluvastatin, pravastatin, lovastatin   144 959/549 336                         1.13\            BMI, CVD, HIV, smoking, alcohol, RA, lymphoma, leukaemia, myeloma, HSCT, OIT, SLE, CKD, COPD, oral corticosteroids, OUCID, DM, asthma, depression, cancer.                                                                                    Selection: 3\
  2016[@R12]                                                                                                                                                                                                                                                                                                                                                                          (1.11 to 1.15)                                                                                                                                                                                                                                                 Comparability: 2\
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     Outcome: 2

  Chen *et al*,\       China    Retrospective cohort   60.1      4.82                   50        ICD code                                                                                                           Prescription               Atorvastatin, rosuvastatin, simvastatin, fluvastatin, pravastatin, lovastatin                 53 069/53 069                           1.21\            Age, sex, CCI score, and comorbidities, HPN, DM, IBD, stroke, cancer, SLE, RA, HIV                                                                                                                                                            Selection: 3 Comparability: 2\
  2015[@R8]                                                                                                                                                                                                                                                                                                                                                                           (1.13 to 1.29)                                                                                                                                                                                                                                                 Outcome: 1

  Antoniou *et al*,\   Canada   Retrospective cohort   73        1.95                   55.2      ICD code or receipt of a prescription for either valaciclovir or famciclovir for the treatment of herpes zoster.   Medication records         Atorvastatin, rosuvastatin, cerivastatin, simvastatin, fluvastatin, pravastatin, lovastatin   494 651/494 651                         1.13\            Age, sex, CCI, CKD, residence, no. of prescription drugs in previous year, medication use, income quintile, MI, angina, HPN, stroke, systemic malignancy, UC, Crohn's disease, SLE, RA, HIV, CABG                                             Selection: 3\
  2014[@R7]                                                                                                                                                                                                                                                                                                                                                                           (1.10 to 1.17)                                                                                                                                                                                                                                                 Comparability: 2\
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     Outcome: 1

  Chung *et al*,\      China    Case control           51.7      2001--2011             53.3      ICD code                                                                                                           Medical orders             Atorvastatin, rosuvastatin, simvastatin, fluvastatin, pravastatin, lovastatin                 47 359/142 077                          1.28\            Age, sex, index year, CHF, MI, liver disease, cancer, dementia, monthly income, geographic location                                                                                                                                           Selection: 2 Comparability: 2\
  2014[@R9]                                                                                                                                                                                                                                                                                                                                                                           (1.24 to 1.32)                                                                                                                                                                                                                                                 Outcome: 2

  Cirillo *et al*,\    USA      Case control           58        2003--2004             3.3       ICD code                                                                                                           Prescription               Atorvastatin, simvastatin, fluvastatin, pravastatin, lovastatin                               8221/10 730                             0.98\            Sex, race, marital status, local VISN, means test group, chronic disease score, died during follow-up, prevalence of elixhauser conditions                                                                                                    Selection: 2\
  2008[@R10]                                                                                                                                                                                                                                                                                                                                                                          (0.82 to 1.17)                                                                                                                                                                                                                                                 Comparability: 2\
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     Outcome: 1
  -----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

AF, atrial fibrillation; BMI, body mass index; CABG, coronary artery bypass grafting; CCI, Charlson Comorbidity Index; CHF, congestive heart failure; CKD, chronic kidney disease; CLD, chronic liver disease; COPD, chronic obstructive pulmonary disease; CPD, chronic pulmonary disease; CRD, chronic renal disease; CVD, cardiovascular disease; DM, diabetes mellitus; HF, heart failure; HPN, hypertension; HSCT, haematopoietic stem cell transplantation; IBD, inflammatory bowel disease; ICD, International Classification of Diseases; IHD, ischaemic heart disease; MI, myocardial infarction; NOS, Newcastle-Ottawa Quality Assessment Scale; OIT, other immunosuppressive therapy; OUCID, other unspecified cellular immune deficiencies; PVD, peripheral vascular disease; RA, rheumatoid arthritis; SLE, systemic lupus erythematosus; TIA, transient ischaemic attack; UC, ulcerative colitis; VHD, valvular heart disease; VISN, Veterans Integrated Service Network.

###### 

Subgroup analyses of risk of herpes zoster among statin users

  Subgroup             OR (95% CI)           No of studies   *I^2^* (%)   P~(heterogeneity)~
  -------------------- --------------------- --------------- ------------ --------------------
  Study type                                                              
   Case control        1.15 (1.03 to 1.29)   3               96           \<0.00
    Cohort             1.19 (1.11 to 1.27)   3               74           0.02
  Study region                                                            
    Asia               1.26 (1.22 to 1.30)   3               11           0.33
    North America      1.08 (0.95 to 1.23)   2               58           0.12
    Europe             1.13 (1.11 to 1.15)   1               NA           NA
  Female percentage                                                       
    ≥50%               1.19 (1.13 to 1.26)   5               93           \<0.00
    \<50%              0.98 (0.82 to 1.17)   1               NA           NA
  Participants                                                            
    ≥200 thousand      1.13 (1.11 to 1.15)   2               0            1.00
    \<200 thousand     1.22 (1.14 to 1.30)   4               70           0.02
  Mean age                                                                
    ≥60 years          1.16 (1.09 to 1.24    2               70           0.07
    \<60 years         1.18 (1.08 to 1.29)   4               94           \<0.00
  Quality of study\*                                                      
   High                1.18 (1.07 to 1.30)   2               81           0.02
    Moderate           1.17 (1.07 to 1.28)   4               92           \< 0.00

\*A total score of 4--6 was considered moderate quality, and 7--9 was deemed high quality.

Statins and herpes zoster {#s3c}
-------------------------

The majority of studies reported a positive association; only one study reported an OR value that was not statistically different than 1.00.[@R10] Three studies reported dose--response analysis,[@R7] but the data could not be used in a dose--response meta-analysis due to different definitions of dose in the different studies. Two of these studies, Matthews *et al* [@R12] (low dose, OR 1.12 (95% CI 1.10 to 1.14); medium dose, OR 1.15 (95% CI 1.11 to 1.18); high dose, OR 1.26 (95% CI 1.15 to 1.39)) and Chen *et al* [@R8] (low dose, OR 0.80 (95% CI 0.76 to 0.85); high dose, OR 2.96 (95% CI 2.74 to 3.20)) showed a higher risk of herpes zoster infection in patients that received a higher dose. Antoniou *et al* [@R7] (medium dose, OR 1.05 (95% CI 1.00 to 1.10); high dose, OR 1.03 (95% CI 0.90 to 1.19)) reported no appreciable difference in the risk of herpes zoster with stain dose.[@R7] Two studies[@R8] reported separate OR calculations for men and women, and one study reported an OR value for male participants that was not statistically significant. The pooled OR from a random-effect model of women was 1.32 (95% CI 1.27 to 1.37, I^2^=0%), and the pooled OR from a random-effect model of men was 1.17 (95% CI 1.05 to 1.31, I^2^=77%). Both male and female patients exhibited a higher risk of herpes zoster, with a slightly higher risk for women. This result needs to be further verified due to the small number of study participants.

The adjusted OR (95% CI) value related to herpes zoster was determined as 1.18 (95% CI 1.11 to 1.25, [figure 2](#F2){ref-type="fig"}). Additionally, we detected an obvious heterogeneity (I^2^=91.2%; p\<0.000).

![The squares and horizontal lines correspond to the study-specific OR and 95% CIs. The area of the squares reflects the study-specific weight. Weights are from random-effect analysis. The diamond represents the pooled OR and 95% CI. ID, identity.](bmjopen-2018-022897f02){#F2}

Publication bias {#s3d}
----------------

There was no publication bias based on the visual inspection of the funnel plot ([figure 3](#F3){ref-type="fig"}) and the result of Egger's test (p=0.646).

![Circles represent identified studies.](bmjopen-2018-022897f03){#F3}

Subgroup and sensitivity analyses {#s3e}
---------------------------------

We conducted subgroup analyses to try to identify the sources of heterogeneity. Analyses were performed by study type, study region, percentage of female, the number of study participants, participant mean age and the quality of study ([table 2](#T2){ref-type="table"}). The subgroup of study region (Asia: I^2^=11%, OR 1.26, 95% CI 1.22 to 1.30; North America: I^2^=58%, OR 1.08, 95% CI 0.95 to 1.23) exhibited marked decreases in heterogeneity. Therefore, we speculated that heterogeneity derives from regional differences. We found no association (OR 1.08, 95% CI 0.95 to 1.23) between statin use and risk of herpes zoster in North America participants, but these results needed to be further verified due to the small number of studies in the different subgroups.

We performed a sensitivity analysis by sequentially omitting each study and then determining if the removal of the study led to a substantial change in the results. We found the study by Chung *et al* was a major source of heterogeneity (from 93% to 65%). We omitted this study, performed the analysis again and found that the result was still significant (OR 1.15, 95% CI 1.11 to 1.19).

Discussion {#s4}
==========

In this meta-analysis of results from more than two million participants, we demonstrated a significantly increased risk of herpes zoster with an overall 1.18-fold increased risk among patients who used statins compared with non-users.

Stains can exhibit some immunomodulatory effects, including improving epithelial cell function, reducing oxidative stress and alleviating inflammation.[@R30] Statins can impair T-cell activation and proliferation,[@R3] and statins can also decrease levels of some proinflammatory cytokines,[@R33] potentially affecting the susceptibility to herpes zoster. One study showed that statins could increase the number of regulatory T cells (Tregs) in vivo,[@R35] but a statin-induced Tregs increase may lead to the reactivation of latent viral infections,[@R21] like the VZV. Overall, the detailed mechanism of how statin use affects VZV remains unclear, and more studies are needed.

We typically associate the use of statins with hyperlipidaemia, but most studies did not assess serum cholesterol levels. This may lead to confounding by indication. Confounding by indication occurs if the effects of treatment indication are ignored, or if factors that may be a consequence of a condition are instead treated as potential causes of that condition.[@R37] A higher dose or longer course of treatment suggests the presence of more serious hyperlipidaemia. Although Chen *et al* [@R8] reported that younger statin users exhibited a higher risk of herpes zoster infection, the major risk factor for herpes zoster is increasing age,[@R38] so the differing results may reflect insufficient adjustment or the consumption by younger patients of a high fat diet leading to high cholesterol level. Furthermore, one study with few participants found that cholesterol levels were associated with herpes zoster in cardiac transplant recipients.[@R40] Although no mechanism has been established, serum cholesterol levels may be associated with the risk of herpes zoster. Statins are prescribed for both primary and secondary CVD,[@R41] so it is unclear if the observed effects are due to the presence of CVD or the risk factors of CVD that increase herpes zoster risk rather than the use of statins. Although these studies tried to adjust for partial risk factors, additional studies are needed.

In our analysis, we found a potential contribution of gender to the risk of herpes zoster among statin users, though the effect was weak. Gender was previously identified as a risk factor of herpes zoster,[@R38] and the use of statins might further increase the risk of infection. The gender difference for infection may indicate effects of sex hormones,[@R43] consistent with the ability of statins to regulate the oestrogen receptor.[@R44] Recently, the use of statins was linked to the occurrence of diabetes[@R45] for patients with no history of diabetes, and the incidence of herpes zoster has been reported to be much higher in patients with diabetes.[@R46] Because women are generally more susceptible to diabetes, these factors may be related. Again, more studies with a large number of participants are needed to confirm the result.

The strengths of our study include the following: we performed a comprehensive systematic search for eligible studies; this is the first systematic review and meta-analysis to specifically evaluate the association between statin use and the risk of herpes zoster; the studies included in our meta-analysis included many participants with long-term follow-up time; literature eligibility was assessed by two investigators independently; no significant publication bias was found.

Several limitations of this meta-analysis should be acknowledged. First, this was a meta-analysis of observational studies, allowing the conclusion that an association exists, but this type of analysis cannot determine if a causal relationship exists. Second, we found significant heterogeneity across studies, due to regional differences. Additionally, the study by Chung *et al* contributed much heterogeneity, but the result remained significant after the exclusion of this study. Third, we did not study the effects of different statins on the risk of herpes zoster due to insufficient data. Fourth, some results might be influenced by the conversion of other measures to OR. Overall, more studies are needed for more robust analysis.

Conclusions {#s5}
===========

Our meta-analysis indicates that the use of statins may increase the risk of herpes zoster. Because the studies included are limited and there is potential bias, further studies are warranted.
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